Opdivo® (nivolumab) – Expanded indication
May 20, 2021 - Bristol Myers Squibb announced the FDA approval of Opdivo (nivolumab), for the adjuvant treatment of completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease in patients who have received neoadjuvant chemoradiotherapy (CRT).
Top